AII
MRTX

AGF Investments Inc’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

AGF Investments Inc’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,618
Closed -$384K – 738
2021
Q4 		$384K Buy
+2,618
New +$406K ﹤0.01% 516

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AGF Investments Inc's MRTX Position: Q1 2022 in Review

AGF Investments Inc sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 2,618 shares — an estimated $384K sold.

AGF Investments Inc first reported a position in MRTX in Q4 2021 and held it in 1 quarter. The position peaked at $384K in Q4 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • AGF Investments Inc reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • AGF Investments Inc sold 2,618 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $384K.
  • AGF Investments Inc first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • AGF Investments Inc's Mirati Therapeutics, Inc. Common Stock position peaked at $384K in Q4 2021.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on AGF Investments Inc's 13F filing for Q1 2022, filed 10 May 2022.